RSC Advances

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard Terms & Conditions and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

www.rsc.org/advances

Page 1 of 22 RSC Advances

ONO Pincer type Pd(II) complexes: Synthesis, crystal structure and catalytic activity towards C-2 arylation of quinoline scaffolds

Vignesh Arumugam^a, Werner Kaminsky^b and Dharmaraj Nallasamy^{a*}

^a Inorganic & Nanomaterials Research Laboratory, Department of Chemistry,

Bharathiar University, Coimbatore 641 046, India.

^bDepartment of Chemistry, University of Washington, Seattle, Washington 98195, USA.

E-mail: dharmaraj@buc.edu.in

Fax: +91 4222422387; Tel: +91 4222428319

ABSTRACT

Four new palladium(II) complexes featuring ONO pincer type hydrazone ligands were synthesized and characterized by spectroscopic and single-crystal XRD analysis. These complexes showed excellent catalytic activity towards Suzuki-Miyaura cross coupling reaction of 2-chloroquinoline derivatives with various aryl boronic acids. The main advantages over previous methodologies include low catalyst loading, less problematic reaction media $(H_2O-DMF (80:20\%)$ and a lower reaction temperature of 60 °C for optimal performance.

INTRODUCTION

Nitrogen based heterocycles are important constituents in a large number of biologically active compounds.¹Among which quinoline scaffolds play a vital role. Several quinolines and their derivatives are currently in use as antibacterial, antifungal, analgesics, antituberculosis, antimalarial, antiinflammatory, anticancer, antibiotic and anti-HIV drugs.² In addition, quinoline analogues are valuable synthons for the preparation of nano and mesostructures with enhanced electronic and photonic properties.³ Despite the numerous pharmacological activities and related synthetic methods,⁴ the development of new, facile and eco-friendly synthetic approaches to 2-substituted quinolines using mild conditions are desirable and subject of ongoing research. 2-Arylated quinoline and their derivatives have proven significant *in vivo* activities against *Leishmaniadonovani* and are in preclinical development.⁵ Likewise, a few other 2-aryl quinolines display significant antiviral activity in HIV-infected cells.⁶

Within the efforts to realize 2-substituted quinolines, most established routines require elevated reaction temperatures, prolonged reaction times, excess amounts of various reagents, including toxic compounds and harsh reaction conditions⁷ which are unsuitable for sensitive substrates and thus constitute a challenge in targeted syntheses. Palladium catalyzed Suzuki-Miyaura cross-coupling (SMC) reactions were tried as an alternative, but unfortunately, nitrogen containing heterocycles are problematic substrates for SMC reactions⁸ because of a tendency to bind with the metal ion and thus deactivates the catalyst.

RSC Advances Page 2 of 22

However, catalysts like $[PdCl_2(PPh_3)_2]$ and $Pd(OAc)_2/D^tBPF$ (D^tBPF = 1,1'-bis(ditertbutylphosphino)ferrocene) were reported to offer improved results compared to the Pd-L catalysts with electron-rich, bulky, monodentate phosphine ligands such as $P^tBu₃$ and $PCy₂$ - (biphenyl), but requiring a high catalyst loading $(5 \text{ mol } 9/6)^8$.^{8(c),9}

Diethyl-{2-[2-(4-propoxy-phenyl)-quinolin -4 -yloxy]-ethyl}-amine

3-Hydroxy-2-phenyl-quinoline -4-carboxylic acid

2-(4-Propoxy-phenyl)-4-(2-pyrrol-1-yl-ethoxy) 2-Phenyl-4-(2-piperidin-4-yl-ethyl) -quinoline -quinoline

Figure1. Biologically active 2-phenylquinoline derivatives

Currently, our group is actively pursuing research on the synthesis and biological applications of hydrazone based transition metal complexes with pincer type geometry.¹⁰ More recently, we turned our attention to evaluate hydrazone based pincer type palladium complexes as catalysts for the SMC reaction.¹¹ Synthesis of transition metal pincer type complexes with high stability and catalytic activity has been a most productive area of homogeneous catalysis and coordination chemistry.^{12,13} The remarkable equilibrium between stability and reactivity of the pincer complexes can be controlled by precise ligand design and subsequent co-operative construction of metal complexes.¹³ As a result, research on the development of pincer ligands possessing CCC, CNC, PNP, SNS, NNN, NCN and SCS donor atoms got much attention.¹⁴ However, studies on ONO pincer ligands and corresponding complexes are scanty in the literature. A recent review on Ru, Ir, W, Ta, Re, Pb, Fe and Sb complexes containing ONO pincer ligand moiety highlighted their importance as catalysts in various organic reactions.^{13a, 15} In our previous study, we reported for the first time, the catalytic potential of¹¹ ONO pincer analogous palladium complexes for SMC of challenging aryl chlorides with various aryl boronic acids bearing activating as well as deactivating substituents.

In this manuscript, we describe the synthesis of four new palladium(II) complexes $(1 – 4)$ bearing ONO pincer type ligands and their catalytic activity towards SMC reaction of 2-chlroroquinoline derivatives with substituted aryl boronic acids. To the best of our insight, this is the first study on the utility of the

Page 3 of 22 RSC Advances

titled complexes as catalysts in SMC reactions of 2-chlroroquinoline derivatives with substituted aryl boronic acids in H_2O-DMF system to synthesis a library of 2-arylquinolines.

RESULTS AND DISCUSSIONS

Direct reactions of palladium precursor $[PdCl_2(PPh_3)_2]$ with the pincer type ligands H_3L1-H_3L4 (where, H3L is pincer type ligand derived from the condensation of salicylaldehyde with salicylichydrazide $(H₃L1)$ or 3-hydroxynaphthoic acid hydrazide($H₃L2$), and 4-methoxysalicylaldehyde with salicylichydrazide (H_3L3) or 3-hydroxynaphthoic acid hydrazide (H_3L4)) yielded complexes 1–4 of the type $[Pd(HL)(PPh_3)]$ as depicted in **Scheme 1**.

Where $R = H$ **or OCH₃**

Scheme 1. Synthesis of ligands and their respective Pd(II) complexes.

IR spectra of the four complexes were compared with corresponding free ligands. The absorption due to free OH groups of the ligands observed respectively, at 3719, 3614, 3610 and 3640 cm⁻¹. A strong band observed at 3185, 3260, 3181, and 3249 cm-1 indicated the presence of a N−H functional group in the free ligands. Intense C=O absorption bands were found at 1618 , 1641 , 1624 , and 1623 cm⁻¹ in the spectrum of the free ligands. All four ligands exhibited a very sharp band at 1555, 1572, 1556, and 1556 attributed to the C=N group. In the IR spectra of the complexes discussed here, non-existence of a strong band from free OH indicated the deprotonation of phenolic oxygen and its coordination to the palladium(II) ion. The N−H and C=O stretching vibrations were missing thus proving that the ligands underwent enolisation followed by deprotonation prior to coordination with the palladium(II) ion.^{16a} In addition, a new band occurred due to the C=N-N=C group at 1494, 1472, 1488, and 1473 cm⁻¹, respectively. The absorption related to a C−O group was identified as a new sharp band at 1255, 1299, 1222 and 1303 cm-1 in for complexes **1** - **4**. The IR spectral features unambiguously prove that the pincer type ligands H_3L1 , H_3L2 , H_3L3 , and H_3L4 were coordinated to palladium(II) ion via the phenolate oxygen, the azomethine nitrogen and the imidolate oxygen in complexes **1**−**4.**16b

¹H NMR spectra of them were recorded in order to study the exact coordination mode of the pincer type ligand in the palladium complexes **1**−**4**. None displayed any signal due to a N−H proton and thus indicated that the oxygen is coordinated to the palladium ion in the imidolate form. Sharp singlet observed in the spectra of complexes **1**–**4** at 8.61, 9.15, 8.20, and 9.39 ppm, respectively were assigned to the azomethine proton of the pincer ligand. The non-involvement of OH groups, despite their presence in the phenyl/naphthyl ring of the corresponding pincer type ligands in coordination with

RSC Advances Page 4 of 22

palladium ion is confirmed by the singlet resonances at 6.38, 5.77, 5.36, and 5.40 ppm, respectively. However, in the spectra of complexes **3,** and **4** a sharp singlet at 3.81 and 3.42 ppm, respectively confirmed the presence of a methoxy group. Aromatic protons present in complexes **1**–**4** were identified in the region of 8.34 to 6.98 ppm.¹⁷ Similarly, the ¹³C NMR resonance of the complexes showed downfield signals at 159.2, 159.3, 159.2, and 157.8 ppm, respectively, owing to the imidolate carbon (N=C–O) involved in coordination. The azomethine carbon of the complexes **1**–**4** gave signals at 151.5, 151.6, 151.5, and 148.5, respectively. Signals featuring in the region of 143.8–105.1 and at 55.2/51.4 ppm have been assigned to aromatic and methoxy carbons present in complexes **1**–**4**. 17

The molecular structure of complexes **1**–**4** were determined by single-crystal X-ray diffraction to study the exact coordination mode of the pincer type ligands with palladium ion. Selected bond angles and bond distances are gathered in Table 1 in the ESI. The ORTEP diagrams provided in Figure 2–5 shows pincer type ligands coordinated to the palladium ion via the phenolate oxygen, azomethine nitrogen and deprotonated imidole oxygen. Complex **1** crystallized in the triclinic system, but the other three were primitive monoclinic with space groups P-1, $P2_1/a$, $P2_1/c$ and $P2_1/c$, respectively. The Pd(II) ion adopts a distorted square-planar geometry in all four structures by accommodating the ligand as a binegative tridentate ONO donor and the fourth site is occupied by a triphenylphosphine. The bite angles of O(1)– Pd(1)–O(2) in **1**–**4** are 174.29(8), 174.30(13), 174.37(6), and 173.74(15), respectively. Similarly, angles N(1)–Pd(1)–P(1) are 174.77(7), 173.09(9), 179.17(5), and 172.74(13). Unit cell packing diagrams of complexes **1**–**4** are provided in ESI. The observed bond lengths and bite angles are very similar to those observed in other palladium(II) complexes.¹⁸ Relevant data concerning data collection and details of the structure refinements are summarized Table 2 in the electronic supplementary information (ESI). Based on ${}^{1}H$, ${}^{13}C$ NMR and single-crystal XRD data, the pincer type hydrazone ligand is coordinated to the palladium ion in a tridentate fashion by replacing both chloride ions and the triphenylphospine from the starting precursor.

Figure 2. ORTEP diagram of complex **1** with thermal ellipsoids at the 50% probability level.

Figure 3. ORTEP diagram of complex **2** with thermal ellipsoids at the 50% probability level.

(Catalyst 2)

Figure 4. ORTEP diagram of complex **3** with thermal ellipsoids at the 50% probability level. (Catalyst 3)

Figure 5. ORTEP diagram of complex **4** with thermal ellipsoids at the 50% probability level. (Catalyst 4)

Table 1. Optimization of reaction conditions

l.

Catalytic activity of the complexes 1–4 were investigated towards SMC reactions of 2 chloroquinoline derivatives with different substituted aryl boronic acids. Reaction conditions were optimized by utilizing 2-chloroquinoline and phenylboronic acid as model substrates in aqueous– organic media and the results are summarized in Table 1.

Initially, the catalytic reaction was studied with various bases such as KOH, NaOH, K_2CO_3 , $NaHCO₃, Na₂CO₃, CH₃COONa, Et₃N, and pyridine, where KOH provided a coupled product of$ 90% isolated yield. No reaction was observed in neat water, because of catalyst insolubility (Table 1, entry 1). This problem was circumvented by adding organic solvents to help dissolve the catalyst in the reaction media. A $80:20\%$ mixture of H₂O-DMF was found to be most effective for the titled coupling reaction. A comparative catalytic study was carried out involving all the four catalysts towards the chosen SMC reaction. Catalysts **2** and **4** performed better than the other two which may be related to a napthyl unit in the coordinated pincer ligand. In particular catalyst **4** with a methoxy substituent in the salicylaldehyde part, is more effective than catalyst **2**, which is composed of non-substituted salicylaldehyde in its molecular architecture. The role of triphenylphosphine ligand in the catalysts **1**–**4** is to help in activating C–Cl bonds in quinolines.¹⁹

Figure 6. Effect of temperature on the SMC reaction.

In addition, the effect of temperature on this coupling reaction was investigated by using 2 chloroquinoline (3 mmol), phenylboronic acid (4 mmol), KOH (5 mmol), catalyst **4** (0.01 mol %) in H2O-DMF (80:20%) and the isolated yield of coupled products were illustrated in Figure 6. A distinct optimum was reached at 60 °C.

To further explore the scope and application of the reaction, we studied the reaction of various aryl boronic acids with 2-chloroquinoline derivatives under the optimized conditions mentioned above. Aryl boronic acids featuring an electron- donating group such as –CH3, –OCH3, *t*– $(CH₃)₃C₋$, –OH, and –NR₂ furnished the reaction smoothly and afforded 65–92% of the coupled products over a period of 4–6 h (Table 2 entries 1c, 1f, 1k, 2c, 2f and 2k). Interestingly, sterically hindered aryl boronic acids afforded a 82–90% yield (Table 2 entries 1b, 1d, 1e, 1g, 1h, 1i, 2b, 2d, 2e, 2g, 2h and 2i). Similarly, boronic acids bearing moderate electron with drawing groups such as Br and –COCH₃ efficiently underwent the coupling reaction, to afford the products in 74–90% (Table 2 entries 1j, 1l, 2j and 2l). Not even a trace of neither homocoupling of aryl boronic acids nor coupling with –OH and –Br groups of the substrates were observed (Table 2, entry 1g, 1j, 2g, and 2j). This offers an opportunity to conduct further cross-coupling reactions by exploiting the halogenated positions available on selective boronic acids (Table 2, entry 1j and $2i$).

Catalyst loading tests of complex **4** revealed best performance for 0.01 mol%. Reducing catalyst stacking from 0.01–0.0001 mol% under optimized conditions resulted in low yield as reported earlier.²⁰ On the other hand, use of 0.0001 mol% catalyst resulted in high turnover number (Table 3).

Reusability of the selected catalyst **4**, 0.01 mol% was screened and the trend of the isolated yield is summarized in Figure 7. A 20 mL round bottom flask was charged with 2-chloroquinoline (3.0 mmol) and phenylboronic acid (4 mmol), KOH (5 mmol) in $H₂O-DMF$ (80:20%). To this reaction mixture was added catalyst 4 (0.01 mol%) and heated to 60 °C. After completion of the reaction, the mixture was extracted with ethyl acetate and the organic layer was subjected to column chromatography to separate the catalyst and product using silica gel and petroleum ether/ ethyl acetate (90/10%) as an eluent. The recovered catalyst was washed with distilled water, dried and utilized for the next cycle under same reaction conditions. The identity of the recovered catalyst was confirmed by R_f value (0.54) and melting point of the original catalyst 219-221 °C. The first cycle afforded 96% of the corresponding coupled product, but yield decreased steadily in subsequent cycles (Figure 7).

Table 2. SMC reaction of 2-chloroquinolines with substituted phenylboronic acids using complex **4** as catalyst*^a*

a =Reaction conditions: 2-chloroquinoline or 6-methyl-2-chloroquinoline (3.0 mmol), aryl boronic acid (4.0 mmol) , 0.01 mol % of complex **4**, KOH (5.0 mmol), H₂O (4 mL), and DMF (1 mL) stirred for 4–6 h at 60 °C.

^b=Isolated yield after column chromatography, TON =Turnover number = ratio of moles of product formed to moles of catalyst used,TOF = Turnover frequency = TON/h.

 Figure 7. Reusability of catalyst **4**

Very recently, P. T. Perumal *et al*²¹ reported a SnCl₂.2H₂O mediated synthesis of 2–substituted quinolines in ethanol via A^3 - coupling followed by reductive cyclization in 89% yield. Advantageously, we herein demonstrated that SMC of aryl boronic acids with 2-chloroquinolines

catalyzed by new ONO pincer type palladium(II) complex led to similar 2-arylquinolines in an excellent yield up to 97% in H₂O-DMF over a period of 4–6 h with low catalyst loading (0.01) mol %).

CONCLUSIONS

Herein, we portrayed the synthesis of four new palladium complexes bearing ONO pincer type ligands along with thorough characterization using IR, ${}^{1}H$ and ${}^{13}C$ NMR and single-crystal XRD techniques. These complexes showed strong performance in the Suzuki–Miyaura coupling reaction between 2-chloroquinoline scaffolds and aryl boronic acids with low catalyst loading in H2O-DMF (80:20%) at moderate temperature. We feel that the present palladium catalyzed methodology offers a simple and straight forward route to synthesize a series of biologically important 2-arylquinolines possessing both activating and deactivating groups in excellent yields.

EXPERIMENTAL SECTION

All chemicals utilized for the synthesis of ligands and their complexes were obtained from Sigma-Aldrich, India. Solvents were purified and dried according to standard procedures.²² Elemental analysis (C, H and N) was performed on a Vario EL III Elemental analyzer instrument. IR spectra (4000–400 cm⁻¹) were recorded on a Nicolet Avatar Model FT-IR spectrophotometer. Melting points were determined with a Lab India instrument.¹H and ¹³C NMR spectra were recorded in deuterated CHCl₃ as solvent on BRUKER 400 and 100 MHZ instruments, respectively.

Synthesis of ligands

Pincer type ligands H₃L were synthesized by condensing equimolar amounts of salicylaldheyde or 4-methoxy salicylaldheyde with salicylhydrazide $(H₃L1$ and $H₃L3$ or 3-hydroxy-2-naphthoic acid hydrazide $(H₃L₂$ and $H₃L₃4$) in ethanol according to literature method (Scheme 1). The reaction mixture was then refluxed on a water-bath for 4 h and poured into crushed ice. The corresponding solid pincer type ligand formed was filtered, washed several times with distilled water and recrystallized from ethanol in 80–90% yield. The purity of the ligands were checked by various analytical techniques and is in accordance with literature reports. 23

General method for the synthesis of the palladium complexes

To a warm methanolic solution (20–30 mL) of appropriate ligands (1 equiv.) were added a chloroform solution of $[PdCl_2(PPh_3)_2]$ (1 equiv.) followed by two drops of triethylamine. The reaction mixture was refluxed 6–7 h and kept at room temperature for crystallization. Needle like

reddish brown crystals suitable for X-ray studies were obtained on slow evaporation over 45–60 days.

[Pd(HL1)(PPh3)] (complex **1)** Yield 71%. M.p. 207–210 °C. Elemental analysis (%) calculated for $C_{32}H_{25}N_2O_3P$ Pd; C, 61.70; H, 4.05; N, 4.50. Found $(\%)$; C, 61.68; H, 4.03; N, 4.46. UVvisible (solvent: DMSO, nm): 296, 313, 372, and 400. Selected IR bands (KBr, *ν* in cm−1): 3322, 1596, 1494, and 1255. ¹H NMR (CDCl₃, δ ppm) 8.61 (s, 1H), 8.34 (d, $J = 9.2$ Hz, 2H), 8.20 (d, *J* = 8 Hz, 2H), 7.56 (t, *J* = 9.8 Hz, 2H), 7.42–7.48 (m, 9H), 7.31–7.41 (m, 4H), 7.28 (d, *J* = 6.8 Hz, 2H), 6.38 (s, 1H). ¹³C NMR (CDCl3, δ ppm) 159.2, 151.5, 143.8, 141.55, 140.3, 137.7, 135.5, 133.7, 132.3, 131.4, 129.3, 128.1, 127.2, 126.5, 126.1, 125.4, 125.1, 124.8, 113.3, 110.0.

[Pd(HL2)(PPh3)] (complex **2)** Yield 69%. M.p. 215–218 °C. Elemental analysis (%) calculated for $C_{36}H_{27}N_2O_3P$ Pd; C, 64.25; H, 4.04; N, 4.16. Found $(^{9}$ ₀); C, 64.23; H, 4.02; N, 4.14. UVvisible (solvent: DMSO, nm): 298, 316, 371, and 400. Selected IR bands (KBr, ν in cm⁻¹): 3322,1593, 1472 and 1299. ¹H NMR (CDCl₃, δ ppm) 9.15 (s, 1H), 8.10 (s, 3H), 7.80–7.84 (m, 6H),7.57 (t, *J* = 7.8 Hz, 5H), 7.48 (t, *J* = 9.6 Hz, 7H), 7.31 (t, *J* = 2.6 Hz, 4H), 5.77 (s, 1H). ¹³C NMR (CDCl₃, δ ppm) 159.3, 151.6, 143.2, 141.7, 137.6, 132.7, 132.6, 132.0, 130.9, 128.5, 128.0, 127.4, 126.3, 126.1, 125.8, 125.1, 124.9, 123.5, 119.8, 114.3, 110.7.

[Pd(HL3)(PPh3)] (complex **3)** Yield 76%. M.p. 212–214 °C. Elemental analysis (%) calculated for C33H27N2O4PPd; C, 60.70; H, 4.17; N, 4.29. Found (%); C, 60.68; H, 4.15; N, 4.26.UVvisible (solvent: DMSO, nm): 299, 316, 360, and 391. Selected IR bands (KBr, *ν* in cm−1): 3416, 1597, 1488, and 1222. ¹H NMR (CDCl3, δ ppm) 8.20 (s, 1H), 7.81 (d, *J* = 7.6 Hz, 4H), 7.53–7.56 (m, 3H), 7.48 (t, *J* = 9.8 Hz, 4H), 7.28–7.39(m, 8H), 6.98 (d, *J* = 8.4 Hz, 3H), 5.36 (s, 1H), 3.81 $(s, 3H)$. ¹³C NMR (CDCl₃, δ ppm) 159.2, 151.5, 143.6, 141.7, 139.4, 137.3, 133.5, 133.1, 132.3, 131.6, 129.4, 128.9, 128.5, 126.5, 126.4, 125.6, 125.3, 124.4, 123.0, 113.6, 110.7, 51.4.

Pd(HL4)(PPh3)] (complex **4)** Yield 74%. M.p. 219–221 °C. Elemental analysis (%) calculated for C37H29N2O4PPd; C, 63.21; H, 4.16; N, 3.98. Found (%);C, 63.20; H, 4.14; N, 3.94. UVvisible (solvent: DMSO, nm): 291, 319, 372, and 401. Selected IR bands (KBr, *ν* in cm−1): 3416, 1593, 1473, and 1303. ¹H NMR (CDCl3, δ ppm) 9.39 (s, 1H), 8.09 (s, 5H), 7.96 (t, *J* = 11.6 Hz, 3H), 7.65 (t, *J* = 8.0 Hz, 4H), 7.59 (d, *J* = 8.0 Hz, 5H), 7.39–750 (m, 4H), 7.37 (d, *J* = 8.0 Hz, 3H), 5.40 (s, 1H), 3.42 (s, 3H). ¹³C NMR (CDCl3, δ ppm) 157.8, 148.5, 143.1, 141.9, 141.8, 136.1, 134.8, 131.1, 129.3, 128.6, 128.1, 127.5, 126.9, 126.5, 126.4, 125.5, 124.6, 123.1, 122.7, 118.6, 105.1, 55.2.

RSC Advances Accepted Manuscript RSC Advances Accepted Manuscript

Single crystal X-ray diffraction studies

Data collection: single-crystal X-ray diffraction data of complexes 1–4 were collected on Bruker APEX II single crystal X-ray diffractometer. The data was integrated and scaled using SAINT / SADABS from within the APEX2 software package by Bruker (Version 2.1-4). Indexing and unit cell refinement indicated complex 1 is triclinic and all other complexes were primitive monoclinic, with space groups P $\overline{1}$, P2₁/a , P2₁/c and P2₁/c, respectively. Solution by direct methods (SHELXS, $SIR97)^{24}$ produced complete heavy atom phasing models consistent with the proposed structures. The structures were completed by difference Fourier synthesis with SHELXL97.^{25,26} Scattering factors are from Waasmair and Kirfel.²⁷ Hydrogen atoms were placed in geometrically idealized positions and constrained to ride on their parent atoms with C–H distances in the range 0.95–1.00 Angstrom. Isotropic thermal parameters Ueq were fixed such that they were 1.2Ueq of their parent atom Ueq for CH's and 1.5Ueq of their parent atom Ueq in case of methyl groups. All non-hydrogen atoms were refined anisotropically by full-matrix leastsquares.

Catalysis

General procedure for Suzuki-Miyaura C–C coupling reaction and recycling of the catalyst-4

A 20 mL round bottom flask was charged with 2-chloroquinoline (3 mmol), phenylboronic acid (4 mmol) and KOH (5 mmol) in H_2O-DMF (80:20%). Then, the catalyst 4 (0.01 mol %) was added to this mixture and stirred at 60 °C. The progress of the SMC reaction was monitored by thin layer chromatography (petroleum ether/ ethyl acetate (90-10%)) and the Rf value of the product was measured to be 0.61. After completion of the reaction, the mixture was solvent diluted with ethyl acetate and dried over anhydrous Na₂SO₄. Solvent was evaporated under vacuo and the residue was purified by column chromatography using petroleum ether/ EtOAc as eluent to afford 2-phenylquinoline as a pale yellow solid. The product was washed with distilled water to remove inorganic base. The identity of the product was confirmed by ${}^{1}H$ and ${}^{13}C$ NMR data.

NMR spectral data of coupled products as listed in Table 3.

 1 ¹H and ¹³C NMR spectra were recorded in deuterated CHCl₃ and DMSO as solvent on BRUKER 400 and 100 MHZ instruments, respectively. The signals corresponding to various protons of the coupled products are assigned by comparison with reported data.²⁸

Entry 1a: 2-phenylquinoline: Elemental analysis (%) calculated for C₁₅H₁₁N; C, 87.77; H, 5.40; N, 6.82. Found (%); C, 87.72; H, 5.38; N, 6.81. ¹H NMR δ (ppm): 7.96 (d, *J* = 8 Hz, 2H), 7.85– 7.91(m, 3H), 7.74 (d, *J* = 7.6 Hz, 1H), 7.32–7.37 (m, 1H), 7.29 (d, *J* = 7.6 Hz, 2H), 7.26 (d, *J* =

9.6 Hz, 1H) 7.16–7.18 (m, 1H). ¹³C NMR: δ (ppm): 157.8, 149.1, 143.1, 140.9, 139.3, 133.7, 130.4, 129.5, 128.3, 128.1, 127.7.

Entry 1b: 2-*o*-tolylquinoline: Elemental analysis $\frac{8}{6}$ calculated for C₁₆H₁₃N; C, 87.64; H, 5.98; N, 6.39. Found (%); C, 87.61; H, 5.95; N, 6.38. ¹H NMR δ (ppm): 7.93 (d, *J* = 8 Hz, 1H), 7.81– 7.86(m, 1H), 7.63(d, *J* = 7.2 Hz, 2H), 7.34–7.37 (m, 1H), 7.29–7.33 (m, 2H), 7.19 (d, *J* = 8.2 Hz, 2H), 7.13 (d, *J* = 7.4 Hz, 1H), 2.38 (s, 3H).¹³C NMR: δ (ppm): 156.7, 148.9, 143.2, 141.0, 139.5, 137.9, 130.3, 129.6, 129.0, 128.8, 128.5, 126.8, 126.6, 125.3, 125.2, 21.3.

Entry 1c: 2-*p*-tolylquinoline: Elemental analysis $\frac{6}{6}$ calculated for C₁₆H₁₃N; C, 87.64; H, 5.98; N, 6.39. Found (%); C, 87.62; H, 5.96; N, 6.37. ¹H NMR δ (ppm): 7.92 (d, *J* = 8.4 Hz, 2H), 7.84 (d, *J* = 8.2 Hz, 1H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.69 (d, *J* = 8 Hz, 1H), 7.25–7.38 (m, 1H), 7.10– 7.23 (m, 2H), 6.91 (d, $J = 7.6$ Hz, 1H), 6.80 (s, 1H), 2.43 (s, 3H), ¹³C NMR: δ (ppm): 158.2, 150.8, 144.2, 140.1, 138.8, 133.3, 130.2, 129.3, 127.9, 127.7, 125.4, 125.1, 124.9, 120.7, 21.6.

Entry 1d: 2-(2,3-dimethyl-phenyl)-quinoline: Elemental analysis (%) calculated for C₁₇H₁₅N; C, 87.52; H, 6.48; N, 6.00. Found (%); C, 87.50; H, 6.46; N, 5.98. ¹H NMR δ (ppm): 8.05 (d, $J =$ 9.2 Hz, 1H),7.91 (q, *J* = 8.6 Hz, 2H), 7.68 (d, *J* = 8 Hz, 1H), 7.40–7.48 (m, 1H), 7.35–7.39 (m, 1H), 7.27–7.34 (m, 1H), 7.19–7.23 (m, 2H), 2.93 (s, 3H), 2.76 (s, 3H).¹³C NMR: δ (ppm): 156.8, 150.4, 142.0, 140.8, 139.1, 138.8, 133.7, 133.4, 130.3, 129.8, 128.9, 128.7, 128.2, 127.7, 125.5, 125.2, 24.4, 21.1.

Entry 1e: 2-(2-methoxy-phenyl)-quinoline: Elemental analysis (%) calculated for C₁₆H₁₃NO; C, 81.68; H, 5.57; N, 5.95. Found (%); C, 81.67; H, 5.55; N, 5.93. ¹H NMR δ (ppm): 7.97 (d, *J* = 8.4 Hz, 1H), 7.82–7.88 (m, 2H), 7.58 (d, *J* = 7.8 Hz, 2H), 7.49 (d, *J* = 6.2 Hz, 1H), 7.47 (d, *J* = 7.5 Hz, 2H), 7.30–7.38 (m, 1H), 7.10–7.19 (m, 1H), 2.90 (s, 3H). ¹³C NMR: δ (ppm): 158.3, 150.9, 142.2, 140.1, 139.6, 128.8, 133.5, 131.8, 130.1, 129.2, 128.9, 128.5, 127.8, 127.7, 127.3, 51.4.

Entry 1f: 2-(4-*tert*-butyl-phenyl)-quinoline: Elemental analysis $\frac{8}{9}$ calculated for C₁₉H₁₉N; C, 87.31; H, 7.33; N, 5.36. Found (%); C, 87.30; H, 7.32; N, 5.34. ¹H NMR δ (ppm): 7.91 (s, 2H), 7.81 (d, *J* = 9.2 Hz, 1H), 7.68 (d, *J* = 9.6 Hz, 1H), 7.31–7.21 (m, 2H), 7.0 (m, 1H), 1.55 (s, 9H). ¹³C NMR: δ (ppm): 157.0, 148.8, 143.1, 141.4, 140.3, 137.4, 135.4, 129.5, 128.7, 128.2, 127.5, 126.8, 126.3, 125.9, 125.3, 124.1, 34.6, 29.6.

Entry 1g: 3-quinolin-2-yl-phenol: Elemental analysis (%) calculated for C₁₅H₁₁NO; C, 81.43; H, 5.01; N, 6.33. Found (%); C, 81.42; H, 4.99; N, 6.29. ¹H NMR δ (ppm): 7.89–7.98 (m,1H), 7.87 $($ s, 2H $)$, 7.71 (d, *J* = 7.6 Hz, 1H $)$, 7.49 (dd, *J* = 2.4, 2.4 Hz, 1H $)$, 7.34 (t, *J* = 8 Hz, 3H $)$, 7.28 (d, *J* $= 7.2$ Hz, 1H), $7.10-7.21$ (m, 1H), 7.08 (s, 1H). ¹³C NMR: δ (ppm): 161.6, 159.1, 148.7, 143.9, 141.3, 140.5, 138.2, 134.7, 134.1, 129.7, 129.6, 128.3, 128.2, 127.0, 126.9, 125.1, 124.5.

Page 17 of 22 RSC Advances

Entry **1h:** 2-naphthalen-2-yl-quinoline: Elemental analysis (%) calculated for C₁₉H₁₃N; C, 89.38; H, 5.13; N, 5.49. Found (%); C, 89.35; H, 5.11; N, 5.45. ¹H NMR δ (ppm): 7.83–7.90 (m, 3H), 7.65 (d, *J* = 11.2 Hz, 1H), 7.50 (d, *J* = 2 Hz, 1H), 7.34 (dd, *J* = 1.6, 8 Hz, 1H), 7.25–7.30 (m, 1H), 7.24 (d, *J* = 1.6 Hz, 2H), 7.20 (t, *J* = 1.4 Hz, 3H), 7.10–7.19 (m, 1H).¹³C NMR: δ (ppm): 155.0, 148.8, 141.1, 140.4, 140.2, 139.5, 136.3, 133.8, 130.3, 129.9, 128.8, 128.6, 128.5, 127.7, 126.5, 125.4, 124.5, 124.0, 119.8, 118.9.

Entry 1i: 2-biphenyl-4-yl-quinoline: Elemental analysis $\frac{N}{2}$ calculated for $C_{21}H_{15}N$; C, 89.65; H, 5.37; N, 4.98. Found (%); C, 89.62; H, 5.34; N, 4.95. ¹H NMR δ (ppm): 7.91–7.94 (m, 2H), 7.88 $(d, J = 8.4 \text{ Hz}, 2\text{H})$, 7.69 $(d, J = 12 \text{ Hz}, 1\text{H})$, 7.31–7.37 (m, 3H) 7.28 $(d, J = 2.8 \text{ Hz}, 2\text{H})$, 7.23 $(d, J = 2.8 \text{ Hz})$ *J* = 7.2 Hz, 3H), 6.99 (d, *J* = 8 Hz, 2H). ¹³C NMR: δ (ppm): 155.0, 147.9, 143.0, 142.7, 139.6, 137.1, 137.0, 129.3, 129.0, 127.9, 126.8, 125.8, 125.1, 119.5, 116.7.

Entry 1*j*: 2-(4-bromo-phenyl)-quinoline: Elemental analysis (%) calculated for $C_15H_{10}BrN$; C, 63.40; H, 3.55; N, 4.93. Found (%); C, 63.38; H, 3.54; N, 4.91. ¹H NMR δ (ppm): 7.48 (d, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 10.4 Hz, 1H), 7.32 (d, *J* = 6.8 Hz, 2H), 7.20–7.23 (m, 2H) 7.07–7.19 (m, 2H), 6.94 (s, 2H).¹³C NMR: δ (ppm): 157.0, 147.6, 142.6, 140.2, 139.2, 137.4, 135.9, 130.3, 128.5, 127.5, 126.1, 125.6, 124.3, 119.4, 116.5, 89.1.

Entry **1k:** dimethyl-(4-quinolin-2-yl-phenyl)-amine: Elemental analysis (%) calculated for C₁₇H₁₆N₂; C, 82.22; H, 6.49; N, 11.28. Found (%); C, 82.20; H, 6.47; N, 11.25. ¹H NMR δ (ppm): 7.96 (d, *J* = 8 Hz, 1H), 7.83–7.87 (m, 2H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.32–7.38 (m, 3H), 7.20–7.27 (m, 1H) 7.14 (d, *J* = 8.8 Hz, 2H), 2.83 (s, 6H). ¹³C NMR: δ (ppm): 156.5, 149.1, 143.4, 141.5, 141.3, 138.2, 133.5, 131.0, 130.2, 128.4, 128.1, 127.5, 127.1, 126.6, 125.5, 125.3, 124.3, 122.6, 37.8.

Entry 11: 1-(4-quinolin-2-yl-phenyl)-ethanone: Elemental analysis (%) calculated for C₁₇H₁₃NO; C, 82.57; H, 5.30; N, 5.66. Found (%); C, 82.56; H, 5.27; N, 5.65. ¹H NMR δ (ppm): 7.91 (d, J = 8.4 Hz, 2H), 7.85 (d, *J* = 7.6 Hz, 2H), 7.63 (d, *J* = 8 Hz, 1H), 7.30–7.37 (m, 1H), 7.25 (d, *J* = 5.6 Hz, 1H), 7.14–7.20 (m, 1H), 6.95 (d, $J = 12.4$ Hz, 2H), 2.92 (s, 3H). ¹³C NMR: δ (ppm): 169.6, 159.3, 143.9, 143.5, 141.7, 141.1, 138.0, 134.1, 134.0, 132.8, 130.3, 128.5, 128.3, 127.7, 127.5, 126.1, 29.0.

Entry 2a: 6-methyl-2-phenyl-quinoline: Elemental analysis $(\%)$ calculated for C₁₆H₁₃N; C, 87.64; H, 5.98; N, 6.39. Found (%); C, 87.61; H, 5.95; N, 6.37. ¹H NMR δ (ppm): 7.82 (s, 1H), 7.80 (d, *J* = 7.4 Hz, 2H), 7.59 (d, *J* = 2 Hz, 2H), 7.57 (t, *J* = 2 Hz, 1H), 7.49–7.55 (m, 3H), 7.37– 7.48 (m, 1H), 2.49 (s, 3H). ¹³C NMR: δ (ppm): 161.2, 148.1, 147.2, 135.7, 135.3, 129.4, 128.3, 128.1, 127.1, 126.4, 123.1, 122.0, 29.0.

Entry 2b: 6-methyl-2-*o*-tolyl-quinoline: Elemental analysis $\frac{6}{6}$ calculated for C₁₇H₁₅N; C, 87.52; H, 6.48; N, 6.00. Found (%); C, 87.50; H, 6.45; N, 5.98. ¹H NMR δ (ppm): 8.50 (s, 1H), 7.93–8.10 (m, 5H), 7.66 (d, *J* = 2 Hz, 2H), 7.50–7.57 (m, 1H), 3.35 (s, 3H) 2.51 (s, 3H). ¹³C NMR: δ (ppm): 160.3, 147.7, 147.4, 135.5, 134.9, 131.9, 128.3, 127.9, 126.9, 122.7, 121.9, 120.9, 120.1, 26.9, 19.8.

Entry 2c: 6-methyl-2-*p*-tolyl-quinoline: Elemental analysis (%) calculated for $C_{17}H_{15}N$; C, 87.52; H, 6.48; N, 6.00. Found (%); C, 87.50; H, 6.45; N, 5.97. ¹H NMR δ (ppm): 8.17 (s, 1H), 7.85 (d, *J* = 7.6 Hz, 2H), 7.79 (d, *J* = 7.6 Hz, 2H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.44 (t, *J* = 7.2 Hz, 1H), 7.00 (d, $J = 2.4$ Hz, 2H), 3.66 (s, 3H), 2.56 (s, 3H).¹³C NMR: δ (ppm): 160.2, 147.9, 147.7, 136.0, 135.2, 133.1, 129.2, 128.6, 128.1, 127.0, 124.2, 121.8, 121.2, 121.1, 112.8, 21.9, 19.4.

Entry **2d:** 2-(2,3-dimethyl-phenyl)-6-methyl-quinoline: Elemental analysis (%) calculated for $C_{18}H_{17}N$; C, 87.41; H, 6.93; N, 5.66. Found (%); C, 87.39; H, 6.91; N, 5.62. ¹H NMR δ (ppm): 8.20 (s, 1H), 8.03 (d, *J* = 8.4 Hz, 1H), 7.84 (d, *J* = 7.6 Hz, 2H), 7.74 (d, *J* = 2.4 Hz, 1H), 7.55 (t, $J = 7.8$ Hz, 2H), 7.43–7.46 (m, 2H), 3.96 (s, 3H), 3.91 (s, 3H), 2.50 (s, 3H). ¹³C NMR: δ (ppm): 160.4, 147.9, 135.6, 134.2, 128.3, 128.0, 127.4, 127.0, 122.9, 122.0, 119.5, 119.4, 111.8, 106.3, 26.8, 19.5, 16.2.

Entry **2e:** 2-(2-methoxy-phenyl)-6-methyl-quinoline: Elemental analysis (%) calculated for $C_{17}H_{15}NO$; C, 81.90; H, 6.06; N, 5.62. Found (%); C, 81.88; H, 6.04; N, 5.59. ¹H NMR δ (ppm): 8.71 (s, 1H), 8.19 (d, *J* = 7.6 Hz, 2H), 7.81 (d, *J* = 7.6 Hz, 2H), 7.68 (d, *J* = 8 Hz, 1H), 7.53 (t, *J* $= 7.8$ Hz, 1H), 7.74–7.46 (m, 1H), 7.20–7.26 (m, 1H) 2.71 (s, 3H), 1.83 (s, 3H). ¹³C NMR: δ (ppm): 160.4, 149.5, 146.4, 135.8, 134.4, 131.1, 129.4, 129.1, 128.8, 128.4, 128.2, 127.9, 127.4, 125.8, 12.9, 120.8, 119.5, 119.4, 111.1, 53.5, 25.1

Entry **2f:** 2-(4-*tert*-butyl-phenyl)-6-methyl-quinoline: Elemental analysis (%) calculated for $C_{20}H_{21}N$; C, 87.23; H, 7.69; N, 5.09. Found (%); C, 87.21; H, 7.66; N, 5.07. ¹H NMR δ (ppm): 8.24 (s, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.75 (d, *J* = 6.8 Hz, 1H), 7.39 (d, *J* = 3.6 Hz, 2H), 7.61 (t, $J = 6.4$ Hz, 1H), 7.40–7.49 (m, 2H), 7.26–7.38 (m, 1H), 2.35 (s, 3H), 1.49 (s, 9H). ¹³C NMR: δ (ppm):161.4, 147.4, 143.9, 139.7, 137.7, 136.5, 131.6, 130.8, 129.3, 129.1, 128.6, 128.3, 127.9, 127.7, 127.5, 126.8, 126.7, 125.3, 123.1, 120.8, 120.4, 119.1, 110.7, 106.5, 31.6, 32.4, 23.4.

Entry 2g: 3-(6-methyl-quinolin-2-yl)-phenol: Elemental analysis (%) calculated for C₁₆H₁₃NO; C, 81.68; H, 5.57; N, 5.95. Found (%); C, 81.65; H, 5.54 N, 5.92. ¹H NMR δ (ppm): 8.26 (s, 1H), 8.06 (d, *J* = 8 Hz, 1H), 7.88 (d, *J* = 7.2 Hz, 1H), 7.68 (t, *J* = 12.4 Hz, 1H), 7.58–7.62 (m, 1H), 7.50–7.56 (m, 1H), 7.45 (t, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 11.6 Hz, 1H), 7.37 (s, 1H), 5.31 (s, 1H), 2.50 (s, 3H). ¹³C NMR: δ (ppm): 158.9, 149.5, 147.1, 138.1, 135.3, 130.1, 129.6, 126.6, 126.3, 123.6, 123.1, 120.7, 119.4, 118.5, 112.8, 25.8.

Page 19 of 22 RSC Advances

Entry 2h: 6-methyl-2-naphthalen-2-yl-quinoline: Elemental analysis $\frac{9}{6}$ calculated for C₂₀H₁₅N; C, 89.19; H, 5.61; N, 5.20. Found $\frac{1}{2}$. C, 89.17; H, 5.59; N, 5.18. ¹H NMR δ (ppm): 8.20 (s, 1H), 7.95 (d, *J* = 6.4 Hz, 4H), 7.59 (d, *J* = 6 Hz, 1H), 7.50 (d, *J* = 2 Hz, 1H), 7.46 (t, *J* = 6 Hz, 2H), 7.42–7.46 (m, 1H), 7.30-7.40 (m, 1H), 2.64 (s, 3H). ¹³C NMR: δ (ppm): 160.4, 147.8, 147.6, 136.3, 135.9, 133.6, 129.3, 127.9, 127.7, 127.0, 125.7, 121.6, 121.3, 121.0,111.9, 23.1.

Entry 2i: 2-biphenyl-4-yl-6-methyl-quinoline: Elemental analysis $\frac{\%}{\%}$ calculated for C₂₂H₁₇N; C, 89.46; H, 5.80; N, 4.74. Found (%); C, 89.45; H, 5.78; N, 4.71. ¹H NMR δ (ppm): 8.07 (s, 2H), 8.05 (d, *J* = 7.2 Hz, 2H), 7.89 (d, *J* = 7.2 Hz, 2H), 7.76 (t, *J* = 9 Hz, 1H), 7.68 (d, *J* = 6.4 Hz, 3H), 7.64 (d, *J* = 5.6 Hz, 1H), 7.43 (t, *J* = 9 Hz, 2H), 7.21–7.37 (m, 1H), 2.50 (s, 3H). ¹³C NMR: δ (ppm): 160.9, 147.9, 146.8, 135.2, 133.9, 128.6, 127.8, 127.3, 126.4, 123.2, 122.0, 120.2, 119.4, 117.4, 109.9, 108.3, 31.1.

Entry 2*j*: 2-(4-bromo-phenyl)-6-methyl-quinoline: Elemental analysis (%) calculated for C₁₆H₁₂BrN; C, 64.45; H, 4.06; N, 4.70. Found (%); C, 64.41; H, 4.03; N, 4.68. ¹H NMR δ (ppm): 7.71 (d, *J* = 7.6 Hz, 2H), 7.60 (s, 1H), 7.41–7.52 (m, 2H), 7.38 (t, *J* = 3 Hz, 1H), 7.31 (s, 2H), 7.21–7.28 (m, 1H), 2.35 (s, 3H). ¹³C NMR: δ (ppm): 152.7, 141.1, 136.8, 130.9, 128.5, 124.8, 124.1, 123.2, 122.4, 119.1, 117.0, 116.4, 26.4.

Entry 2k: dimethyl-[4-(6-methyl-quinolin-2-yl)-phenyl]-amine: Elemental analysis (%) calculated for $C_{18}H_{18}N_2$; C, 82.41; H, 6.92; N, 10.68. Found (%); C, 82.39; H, 6.89; N, 10.66. ¹H NMR δ (ppm): 7.79 (d, *J* = 12.8 Hz, 2H), 7.51 (t, *J* = 12.2 Hz, 2H), 7.44 (t, *J* = 7.2 Hz, 1H), 7.36 (t, $J = 6.8$ Hz, 1H), 7.29–7.34 (m, 2H), 6.92–7.15 (m, 1H), 2.96m (s, 6H), 2.34 (s, 3H). ¹³C NMR: δ (ppm): 158.3, 141.9, 137.0, 133.5, 130.8, 128.2, 123.2, 122.4, 120.8, 119.8, 118.7, 115.4, 36.7, 29.4.

Entry **2l:** 1-[4-(6-methyl-quinolin-2-yl)-phenyl]-ethanone: Elemental analysis (%) calculated for $C_{18}H_{15}NO$; C, 82.73; H, 5.79; N, 5.36. Found (%); C, 82.71; H, 5.76; N, 5.32. ¹H NMR δ (ppm): 8.01 (d, *J* = 11.2 Hz, 2H), 7.96 (d, *J* = 12.2 Hz, 2H), 7.74 (d, *J* = 14.4 Hz, 2H), 7.52 (t, *J* = 10.4 Hz, 2H), 7.30–7.43 (m, 1H), 3.31 (s, 3H), 2.84 (s, 3H). ¹³C NMR: δ (ppm): 170.9, 158.3, 140.5, 136.7, 135.4, 133.1, 129.0, 128.8, 125.6, 124.6, 124.1, 123.7, 121.0, 114.8, 29.3, 24.2.

ACKNOWLEDGMENT

Mr. Vignesh Arumugam thanks the University Grants Commission (UGC), New Delhi, India, for the award of Junior Research Fellowship (JRF) under UGC-BSR RFSMS.

References

- 1) M. S.Butler, *J. Nat. Prod*., 2004**, 67**, 2141.
- 2) (a) M. D. Ferretti, A. T. Neto, A. F. Morel, T. S. Kaufman and L. Enrique, *Eur. J. Med. Chem*., 2014, **81**, 253; (b) S. Vandekerckhove, S. V. Herreweghe, J. Willems, B. Danneels, T. Desmet, C. Kock , P. J. Smith, K. Chibale, M. Dhooghe, *Eur. J. Med. Chem*., 2015, **92**, 91; (c) A. H. Abadi, G. H. Hegazy and A. A. El-Zaher, *Bioorg. Med. Chem*., 2005, **13**, 5759; (d) G. C. Muscia, G. Y. Buldain and S. E. Asis, *Eur. J. Med. Chem*., 2014, **73**, 243; (e) A. P. Gorka, A. Dios, and P. D. Roepe, *J. Med. Chem*., 2013, **56**, 5231; (f) S. Mukherjee and M. Pal, *Drug Discov. Today*., 2013, **18**, 389; (g) J. A. Makawana, C. B. Sangani, L. Lin and H. L. Zhu, *Bioorg. Med. Chem*., 2014, **24**, 1734; (h) N. C. Desai, G. M. Kotadiya, A. R. Trivedi, *Bioorg. Med. Chem*., 2014, **24**, 3126; (i) A. Fournet, R. Hocquemiller, F. Roblot, A. Cave, P. Richomme and J. Bruneton, *J. Nat. Prod*., 1993**, 56**, 1547.
- 3) (a) A. K. Aggarwal and S. A. Jenekhe, *Macromolecules*, 1991, **24**, 6806; (b) X. Zhang, A. S. Shetty and S. A. Jenekhe., *Macromolecules*, 1999, **32**, 7422; (c) S. A. Jenekhe, L. Lu and M. M. Alam, *Macromolecules*, 2001, **34**, 7315.
- 4) (a) P. Selig and W. Raven, *Org.Lett.*, 2014, **16**, 5192; (b) L. Kong, Y. Zhou, H. Huang, Y. Yang, Y. Liu and Y. Li, *J. Org. Chem.*, 2015, **80**, 1275; (c) C. E. Meyet and C. H. Larsen, *J. Org. Chem*., 2014, **79**, 9835; (d) N. He , Y. Huo , J. Liu, Y. Huang , S. Zhang and Q.Cai, *Org. Lett.*, 2015, **17**, 374.
- 5) (a) V. S. Gopinath, J. Pinjari, T. D. Ravindra, V. Aditya, V. Preeti, S. Rahul, M. Manjunath, P. S. K. Goud, R. Vikram, P. Bose, M. V. S. Rao, G. Suman, S. K. Puri, D. Launay and D. Martin, *Eur. J. Med. Chem*., 2013, **69**, 527; (b) K. C. Fang, Y. L. Chen, J. Y. Sheu, T. C. Wang and C. C. Tzeng, *J. Med. Chem*., 2000, **43**, 3809; (c) J. Chevalier, S. Atifi, A. Eyraud, A. Mahamoud, J. M . Barbe, *J. Med. Chem*., 2001, **44**, 4023; (d) L. T. Phan, T. Jian, Z. Chen, Y. L. Qiu, Z. Wang, T. Beach, A. Polemeropoulos, Y. S. Or, *J. Med. Chem*., 2004, **47**, 2965.
- 6) J. Polanski, F. Zouhiri, L. Jeanson, D. Desmaele, J. Angelo, J. Mouscadet, R. Gieleciak, J. Gasteiger and M. Le Bret, *J. Med. Chem.*, 2002, **45**, 4647.
- 7) (a) S. Fan, J. Yang and X. Zhang, *Org. Lett*., 2011, **13**, 4374; (b) X. Ren, P. Wen, X. Shi, Y. Wang, J. Li, S. Yang, H. Yan and G. Huang, *Org. Lett*., 2013, **15,** 5194; (c) S. Zhu, L. Wu and X. Huang, *J. Org. Chem*., 2013, **78**, 9120; (d) O. V. Larionov, D. Stephens, A. Mfuh and G. Chavez, *Org. Lett.*, 2014, **16**, 864; (e) L. Kong, Y. Zhou, H. Huang, Y. Yang, Y. Liu and Y. Li, *J. Org. Chem*., 2015, **80**, 1275.
- 8) (a) M. Feuerstein, H. Doucet and M. Santelli, *Tetrahedron Lett*., 2005, **46**, 1717; (b) M. M. Manas, R. Pleixats and A. S.Muns, *Synlett*., 2006, **18**, 3001; (c) T. Itoh and T. Mase, *Tetrahedron Lett*., 2005, **46**, 3573.

Page 21 of 22 **RSC Advances**

- 9) (a) A. E. Thompson, G. Hughes, A. S. Batsanov, M. R. Bryce, P. R. Parry and B. Tarbit, *J. Org. Chem.*, 2005, **70**, 388.
- 10) (a) P. Krishnamoorthy, P. Sathyadevi, R. R. Butorac, A. H. Cowley, N. S. P. Bhuvanesh and N. Dharmaraj, *Dalton Trans*., 2012, **41**, 6842. (b) P. Sathyadevi, P. Krishnamoorthy, N. S. P. Bhuvanesh, P. Kalaiselvi, V. Vijaya Padma and N. Dharmaraj, *Eur. J. Med. Chem*., 2012, **55**, 420. (c) P. Sathyadevi, P. Krishnamoorthy, E. Jayanthi, R. R. Butorac, A. H. Cowley and N. Dharmaraj *Inorg. Chim. Acta*, 2012, **384**, 83. (d) P. Sathyadevi, P. Krishnamoorthy, K. Thanigaimani, P. T. Muthiah and N. Dharmaraj, *Polyhedron*, 2012, **31**, 294. (e) P. Krishnamoorthy, P. Sathyadevi, K. Senthilkumar, P. T. Muthiah, R. Ramesh and N. Dharmaraj, *Inorg. Chem. Commun*., 2011, **14**, 1318. (f) P. Krishnamoorthy, P. Sathyadevi, R. R. Butorac, A. H. Cowley and N. Dharmaraj, *Eur. J. Med. Chem*., 2011, 46, 3376.
- 11) A. Vignesh, W. Kaminsky, N. S. P. Bhuvanesh, N. Dharmaraj, *RSC Adv*., 2015**, 5***,* 59428.
- 12) (a) C. J. Moulton, and B. L. Shaw, *J. Chem. Soc*., *Dalton Trans*., 1976, 1020; (b) C. Crocker, R. J. Errington, W. S. McDonald, K. J. Odell, B. L. Shaw, R. J. Goodfellow, *J. Chem. Soc*. *Chem. Commun.* 1979, 498.
- 13) (a) M. E. Reilly and A. S. Veige, *Chem. Soc. Rev*., 2014, **43,** 6325; (b) J. T. Singleton, *Tetrahedron*, 2003, **59**, 1837. (c) E. V. Peris and R. H. Crabtree, *Coord. Chem. Rev.* 2004, **248**, 2239. (d) M. E. Boom and D. Milstein, *Chem. Rev.* 2003, **103***,* 1759.
- 14) (a) T. O. Howell, A. J. Huckaba and T. K. Hollis, *Org. Lett*., 2014, **16**, 2570; (b) A. M. Prokhorov, T. Hofbeck, R. Czerwieniec, A. F. Suleymanova, D. N. Kozhevnikov and H. Yersin, *J. Am. Chem. Soc*., 2014, **136**, 9637; (c) A. J. Holmes, P. J. Rayner, M. J. Cowley, G. G . R. Green, A. C. Whitwood and S. B. Duckett, *Dalton Trans*., 2015, **44**, 1077; (d) Y. Komiyama, J. Kuwabara and T. Kanbara, *Organometallics*, 2014, **33**, 885; (e) P. García, P. Ren, R. Scopelliti and X. Hu, *ACS Catal*., 2015, **5**, 1164; (f) Q. Deng, R. L. Melen and L. H. Gade, *Acc. Chem. Res.*, 2014, **47**, 3162; (f) G. Mancano, M. Bhadbhade and B. A. Messerle, *Inorg. Chem.*, 2014, **53**, 10159; (g) S. M. Peterson, M. L. Helm and A. M. Appel, *Dalton Trans*., 2015, **44**, 747.
- 15) Y. Zhang, X. Li and S. H. Honga, *Adv. Synth. Catal*., 2010, **352,** 1779.
- 16) (a) A. R. B. Rao and S. Pal, *J. Organomet. Chem*., 2013, **731**, 67. (b) R. N. Prabhu, R. Ramesh, *J. Organomet. Chem*., 2012, **718**, 43.
- 17) M. M. Tamizh and R. Karvembu, *Inorg. Chem. Commun*., 2012**, 25**, 30.
- 18) (a) M. M. Tamizh, B. F. T .Cooper, C. L. B. Macdonald and R. Karvembu, *Inorg. Chim. Acta*, 2013, **394**, 391. (b) A. R. B. Rao, S. Pal, *J. Organomet. Chem*., 2014, **762**, 58.
- 19) L. Botella and C. Najera, *Angew. Chem. Int. Ed*., 2002, **41,** 179.
- 20) (a) M. T. Reetz and J. G. Vries, *Chem. Commun*., 2004**, 14**, 1559. (b) A. V. Gaikwad, A. Holuigue, M. B. Thathagar, J. E. Elshof and G. Rothenberg, *Chem. Eur. J*., 2007**, 13***,* 6908.
- 21) N. Sudhapriya, A. Nandakumar and P.T. Perumal, *RSC Adv*., 2014, **4**, 58476.
- 22) A. I. Vogel, Text Book of Practical Organic Chemistry, 5th ed. Longman: London, 1989.
- 23) A. Syamal and D. Kumar, *Transition Met. Chem*., 1982, **7**, 118.
- 24) A. Altomare, C. Burla, M. Camalli, G. L. Cascarano, C. Giacovazzo, A. Guagliardi, , A. G. G. Moliterni, G. Polidori and R. Spagna, *J. Appl. Cryst*., 1999**, 32,** 115.
- 25) A. Altomare, G. L. Cascarano, C. Giacovazzo and A.Guagliardi, *J. Appl. Cryst*., 1993, **26,** 343.
- 26) S. Mackay, C. Edwards, A. Henderson, C. Gilmore, N. Stewart, K. Shankland, D. A. MaXus, A computer program for the solution and refinement of crystal structures from diffraction data. University of Glasgow; Scotland: 1997.
- 27) D. Waasmaier and A. Kirfel, *Acta Cryst. A*, 1995, **51**, 416.
- 28) (a) Y. Rulong, L. Xingxing, P. Congming, Z. Xiaoqiang, L. Xiaoni, K. Xing and H. Guosheng, *Org. Lett*., 2013, **15,** 4876. (b) C. A. Fleckenstein and H. Plenio, *Green Chem.*, 2007, **9,** 1287. (c) E. M. Courtney, H. L. Catharine, *J. Org. Chem*., 2014, **79,** 9835. (d) X. Fuhong, C. Wen, L. Yunfeng, D. Guo-Jun, *Org. Biomol. Chem*., 2012, **10,** 8593. (e) T. P. Nitin and S. R. Vivek, *J. Org. Chem*., 2010, **75,** 6961.